S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
NASDAQ:CALT

Calliditas Therapeutics AB (publ) - CALT Stock Forecast, Price & News

$22.40
-0.72 (-3.11%)
(As of 03/28/2023 03:59 PM ET)
Add
Compare
Today's Range
$21.92
$23.00
50-Day Range
$16.80
$25.24
52-Week Range
$10.82
$25.49
Volume
13,687 shs
Average Volume
14,859 shs
Market Capitalization
$667.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$79.00

Calliditas Therapeutics AB (publ) MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
249.9% Upside
$79.00 Price Target
Short Interest
Healthy
0.08% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.39mentions of Calliditas Therapeutics AB (publ) in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.47) to $4.42 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

688th out of 1,002 stocks

Pharmaceutical Preparations Industry

338th out of 488 stocks


CALT stock logo

About Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Stock

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Receive CALT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Calliditas Therapeutics AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

CALT Stock News Headlines

Banking Nightmare
During and after the Great Financial Crisis of 2008, 485 U.S. banks went under. Here at Weiss Ratings, we warned about 484 — an accuracy rate of 99.8%. Now, we have a new warning. But this time, it's not just about a few hundred banks … it's about nearly every single bank in America …
Calliditas Therapeutics AB ADR
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Calliditas Therapeutics reports Q4 results
Calliditas - Year-End Report, 2022
Calliditas Therapeutics: Interim Report Q3, 2022
See More Headlines
Receive CALT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Calliditas Therapeutics AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

CALT Company Calendar

Last Earnings
11/17/2021
Today
3/28/2023
Next Earnings (Estimated)
5/17/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CALT
Fax
N/A
Employees
66
Year Founded
2004

Price Target and Rating

Average Stock Price Forecast
$79.00
High Stock Price Forecast
$79.00
Low Stock Price Forecast
$79.00
Forecasted Upside/Downside
+249.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-40,860,000.00
Pretax Margin
-50.99%

Debt

Sales & Book Value

Annual Sales
$79.63 million
Book Value
$2.55 per share

Miscellaneous

Free Float
29,131,000
Market Cap
$672.66 million
Optionable
Not Optionable
Beta
1.48

Social Links


Key Executives

  • Ms. Renee Aguiar-Lucander (Age 60)
    Chief Exec. Officer
  • Mr. Fredrik Johansson (Age 45)
    Chief Financial Officer
  • Dr. Katayoun Welin-Berger Ph.D. (Age 54)
    VP of Operations
  • Dr. Johan Haggblad Ph.D. (Age 64)
    Chief Scientific Officer
  • Mr. Mikael Widell (Age 64)
    Head of Communications & IR
  • Mr. Jonathan A. Schur (Age 69)
    Group Gen. Counsel
  • Ms. Sandra Frithiof
    Head of HR
  • Ms. Ann-Kristin Myde BSc (Age 67)
    Head of Clinical Devel. & VP of Project Management
  • Mr. Andrew B. Udell B.Sc. (Age 52)
    M.B.A., Pres of North America Commercial
  • Dr. Krassimir Mitchev (Age 63)
    Head of Medical Affairs













CALT Stock - Frequently Asked Questions

Should I buy or sell Calliditas Therapeutics AB (publ) stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Calliditas Therapeutics AB (publ) in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CALT shares.
View CALT analyst ratings
or view top-rated stocks.

What is Calliditas Therapeutics AB (publ)'s stock price forecast for 2023?

4 brokerages have issued twelve-month price objectives for Calliditas Therapeutics AB (publ)'s shares. Their CALT share price forecasts range from $79.00 to $79.00. On average, they expect the company's stock price to reach $79.00 in the next twelve months. This suggests a possible upside of 249.9% from the stock's current price.
View analysts price targets for CALT
or view top-rated stocks among Wall Street analysts.

How have CALT shares performed in 2023?

Calliditas Therapeutics AB (publ)'s stock was trading at $17.00 at the start of the year. Since then, CALT stock has increased by 32.8% and is now trading at $22.58.
View the best growth stocks for 2023 here
.

Are investors shorting Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 22,700 shares, an increase of 58.7% from the February 28th total of 14,300 shares. Based on an average trading volume of 14,300 shares, the short-interest ratio is presently 1.6 days.
View Calliditas Therapeutics AB (publ)'s Short Interest
.

When is Calliditas Therapeutics AB (publ)'s next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 17th 2023.
View our CALT earnings forecast
.

How were Calliditas Therapeutics AB (publ)'s earnings last quarter?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) announced its quarterly earnings results on Wednesday, November, 17th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.62. The company earned $22.92 million during the quarter. Calliditas Therapeutics AB (publ) had a negative trailing twelve-month return on equity of 55.18% and a negative net margin of 56.10%. During the same period in the prior year, the business earned ($0.62) earnings per share.

What other stocks do shareholders of Calliditas Therapeutics AB (publ) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Calliditas Therapeutics AB (publ) investors own include Ampio Pharmaceuticals (AMPE), Trevena (TRVN), Advanced Micro Devices (AMD), ChromaDex (CDXC), Chimerix (CMRX), CTI BioPharma (CTIC), DRDGOLD (DRD), Forte Biosciences (FBRX).

When did Calliditas Therapeutics AB (publ) IPO?

(CALT) raised $179 million in an initial public offering (IPO) on Friday, June 5th 2020. The company issued 9,200,000 shares at a price of $19.50 per share. Citigroup, Jefferies and Stifel acted as the underwriters for the IPO and Carnegie was co-manager.

What is Calliditas Therapeutics AB (publ)'s stock symbol?

Calliditas Therapeutics AB (publ) trades on the NASDAQ under the ticker symbol "CALT."

Who are Calliditas Therapeutics AB (publ)'s major shareholders?

Calliditas Therapeutics AB (publ)'s stock is owned by many different retail and institutional investors. Top institutional investors include HBK Sorce Advisory LLC (0.30%), Ironwood Investment Management LLC (0.09%), Optiver Holding B.V. (0.04%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Calliditas Therapeutics AB (publ)?

Shares of CALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Calliditas Therapeutics AB (publ)'s stock price today?

One share of CALT stock can currently be purchased for approximately $22.58.

How much money does Calliditas Therapeutics AB (publ) make?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) has a market capitalization of $672.66 million and generates $79.63 million in revenue each year. The company earns $-40,860,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis.

How can I contact Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ)'s mailing address is KUNGSBRON 1 C8, STOCKHOLM V7, 11122. The official website for the company is www.calliditas.se. The company can be reached via phone at 46-0-841-130-05 or via email at mikael.widell@calliditas.com.

This page (NASDAQ:CALT) was last updated on 3/28/2023 by MarketBeat.com Staff